LivaNova (NASDAQ:LIVN) Hits New 1-Year Low – Here’s What Happened

LivaNova PLC (NASDAQ:LIVN) reached a new 52-week low during trading on Thursday . The company traded as low as $40.03 and last traded at $40.02, with a volume of 70886 shares trading hands. The stock had previously closed at $40.87.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on LIVN shares. Stifel Nicolaus lowered their price target on LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Needham & Company LLC decreased their price target on LivaNova from $75.00 to $64.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 26th. The Goldman Sachs Group decreased their price target on LivaNova from $64.00 to $55.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $62.20.

LivaNova Price Performance

The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The stock has a market capitalization of $2.15 billion, a price-to-earnings ratio of 94.10 and a beta of 1.10. The company has a 50-day moving average of $47.08 and a 200-day moving average of $49.43.

Insider Buying and Selling

In related news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. grew its stake in shares of LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after buying an additional 219 shares during the period. Summit Investment Advisors Inc. grew its stake in shares of LivaNova by 1.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 16,846 shares of the company’s stock valued at $780,000 after buying an additional 289 shares during the period. Atria Investments Inc grew its stake in shares of LivaNova by 6.2% during the 3rd quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after buying an additional 331 shares during the period. State of Alaska Department of Revenue boosted its position in LivaNova by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company’s stock worth $328,000 after purchasing an additional 425 shares during the period. Finally, Xponance Inc. boosted its position in LivaNova by 6.1% during the 4th quarter. Xponance Inc. now owns 7,762 shares of the company’s stock worth $359,000 after purchasing an additional 445 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.